RADAR-base platform recognized as excellent innovation by European Commission

We are very delighted and proud to announce that the RADAR-base platform has been identified as an excellent innovation by the European Commission’s Innovation Radar platform.

The Innovation Radar platform builds on the information and data gathered by independent experts involved in reviewing ongoing research and innovation projects funded by the European Commission. These experts also provided an independent view regarding the innovations in the projects and their market potential.

The Hyve and King’s College London have been identified as key innovators based on our shared role in designing and developing the open source RADAR-base platform, which enables remote assessment of study participants using wearable devices and mobile applications.

The platform was initially developed under the framework of IMI RADAR-CNS, further improved in IMI RADAR-AD and is currently used in multiple remote studies in a wide range of medical fields, covering diseases of the central nervous system, dementia such as Alzheimer’s disease, cardiovascular diseases, disorders of the autism spectrum and many more.

Additional information will be published on the European Commission’s Innovation Radar platform soon.

Funding statement and Disclaimer

The RADAR-base platform was developed under projects IMI RADAR-CNS, IMI RADAR-AD, Bigdata@Heart and IMI H2O which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement numbers 115902, 806999, 116074 and 945345 respectively. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. See www.imi.europa.eu for more details.

Neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained on this website.